ADAM18

Across TCGA pan-cancer cohorts, ADAM18 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated ADAM18 data layer compared with 6 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher ADAM18 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ADAM18 expression acts as an unfavorable survival marker, although some lineages such as KIRC and OV show a favorable association.

MESO, KICH, and LIHC are the cancer types where ADAM18 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.257	0.485	<.001	74	view →
KICH	OS	Tertile	II,III,IV	0.093	0.841	<.001	60	view →
LIHC	OS	Tertile	All	0.651	0.794	.005	45	view →
KIRP	DFS	Quartile	All	0.734	0.892	.001	40	view →
STAD	DFS	Median	II,III,IV	0.452	0.579	.009	37	view →
READ	DFS	Tertile	IV	0.182	0.668	.008	27	view →
KIRC	DFS	Quartile	III,IV	0.735	0.494	.012	26	view →
UCEC	DFS	Quartile	All	0.842	0.914	.002	22	view →
BLCA	OS	Tertile	IV	0.397	0.681	<.001	19	view →
OV	OS	Tertile	IV	0.926	0.658	.008	16	view →
LGG	OS	Tertile	All	0.312	0.511	.015	9	view →
PCPG	DFS	Tertile	All	0.535	0.936	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

ADAM18–MESO (OS)

Open the MESO breakdown →